Future strategies for the treatment of cryptococcal meningoencephalitis in pediatric patients

Bibliography

• Goldman D. Cryptococcus. Elsiever, Philadelphia, PA; 2013
   Google Scholar
• Chen SC, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012;55:789-98
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322
   PubMed Web of Science ®Google Scholar
• Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006;20:507-44. v-vi
   PubMed Web of Science ®Google Scholar
• Thompson GR. Cryptococcus species. Elsevier, China; 2012
   Google Scholar
• Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 1994;14:4912-19
   PubMed Web of Science ®Google Scholar
• Kozel TR, Gotschlich EC. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 1982;129:1675-80
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Retini C, Monari C, et al. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996;64:2846-9
   PubMedGoogle Scholar
• Yauch LE, Lam JS, Levitz SM. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog 2006;2:e120
   PubMedGoogle Scholar
• Dong ZM, Murphy JW. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun 1995;63:2632-44
   PubMed Web of Science ®Google Scholar
• Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986;51:218-23
   PubMed Web of Science ®Google Scholar
• Huffnagle GB, Chen GH, Curtis JL, et al. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol 1995;155:3507-16
   PubMed Web of Science ®Google Scholar
• Nosanchuk JD, Casadevall A. The contribution of melanin to microbial pathogenesis. Cell Microbiol 2003;5:203-23
   PubMed Web of Science ®Google Scholar
• Valdez PA, Vithayathil PJ, Janelsins BM, et al. Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells. Immunity 2012;36:668-79
   PubMed Web of Science ®Google Scholar
• Polacheck I, Platt Y, Aronovitch J. Catecholamines and virulence of Cryptococcus neoformans. Infect Immun 1990;58:2919-22
   PubMedGoogle Scholar
• Osterholzer JJ, Surana R, Milam JE, et al. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am J Pathol 2009;174:932-43
   PubMedGoogle Scholar
• Cox GM, McDade HC, Chen SC, et al. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol 2001;39:166-75
   PubMed Web of Science ®Google Scholar
• Maruvada R, Zhu L, Pearce D, et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol 2012;14:1544-53
   PubMed Web of Science ®Google Scholar
• Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994;19:1029-33
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Brandt ME, Pinner RW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 1995;17:303-20
   PubMed Web of Science ®Google Scholar
• Littman ML, Schneierson SS. Cryptococcus neoformans in pigeon excreta in New York City. Am J Hyg 1959;69:49-59
   PubMed Web of Science ®Google Scholar
• Levitz SM, Nong SH, Seetoo KF, et al. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 1999;67:885-90
   PubMed Web of Science ®Google Scholar
• Chang YC, Stins MF, McCaffery MJ, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 2004;72:4985-95
   PubMed Web of Science ®Google Scholar
• Shi M, Li SS, Zheng C, et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 2010;120:1683-93
   Google Scholar
• Charlier C, Nielsen K, Daou S, et al. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun 2009;77:120-7
   PubMed Web of Science ®Google Scholar
• Shao X, Mednick A, Alvarez M, et al. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol 2005;175:3244-51
   PubMed Web of Science ®Google Scholar
• Hoag KA, Lipscomb MF, Izzo AA, et al. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 1997;17:733-9
   PubMed Web of Science ®Google Scholar
• Kawakami K, Qifeng X, Tohyama M, et al. Contribution of tumour necrosis factor-alpha (TNF-alpha) in host defence mechanism against Cryptococcus neoformans. Clin Exp Immunol 1996;106:468-74
   PubMed Web of Science ®Google Scholar
• Abe K, Kadota J, Ishimatsu Y, et al. Th1-Th2 cytokine kinetics in the bronchoalveolar lavage fluid of mice infected with Cryptococcus neoformans of different virulences. Microbiol Immunol 2000;44:849-55
   PubMedGoogle Scholar
• Curtis JL, Huffnagle GB, Chen GH, et al. Experimental murine pulmonary cryptococcosis. Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab Invest 1994;71:113-26
   PubMedGoogle Scholar
• Haugen RK, Baker RD. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol 1954;24:1381-90
   PubMedGoogle Scholar
• Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999;37:3204-9
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58:1-166
   PubMedGoogle Scholar
• Abadi J, Nachman S, Kressel AB, et al. Cryptococcosis in children with AIDS. Clin Infect Dis 1999;28:309-13
   PubMed Web of Science ®Google Scholar
• Gonzalez CE, Shetty D, Lewis LL, et al. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:796-800
   PubMed Web of Science ®Google Scholar
• Leggiadro RJ, Kline MW, Hughes WT. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991;10:658-62
   PubMed Web of Science ®Google Scholar
• Joshi NS, Fisher BT, Prasad PA, et al. Epidemiology of cryptococcal infection in hospitalized children. Pediatr Infect Dis J 2010;29:e91-5
   PubMedGoogle Scholar
• Meiring ST, Quan VC, Cohen C, et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005-2007. AIDS 2012;26:2307-14
   PubMedGoogle Scholar
• Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health 2004;35:935-9
   PubMedGoogle Scholar
• Blackstock R, Murphy JW. Age-related resistance of C57BL/6 mice to Cryptococcus neoformans is dependent on maturation of NKT cells. Infect Immun 2004;72:5175-80
   PubMedGoogle Scholar
• Lortholary O, Improvisi L, Fitting C, et al. Influence of gender and age on course of infection and cytokine responses in mice with disseminated Cryptococcus neoformans infection. Clin Microbiol Infect 2002;8:31-7
   PubMedGoogle Scholar
• Aguirre KM, Gibson GW, Johnson LL. Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge. Infect Immun 1998;66:4018-24
   PubMedGoogle Scholar
• Miglia KJ, Govender NP, Rossouw J, et al. Analyses of pediatric isolates of Cryptococcus neoformans from South Africa. J Clin Microbiol 2011;49:307-14
   PubMedGoogle Scholar
• Bouklas T, Pechuan X, Goldman DL, et al. Old Cryptococcus neoformans cells contribute to virulence in chronic cryptococcosis. MBio 2013;4:e00455-13
   Google Scholar
• Leggiadro RJ, Barrett FF, Hughes WT. Extrapulmonary cryptococcosis in immunocompromised infants and children. Pediatr Infect Dis J 1992;11:43-7
   PubMed Web of Science ®Google Scholar
• Wahab JA, Hanifah MJ, Choo KE. Bruton's agammaglobulinaemia in a child presenting with cryptococcal empyema thoracis and periauricular pyogenic abscess. Singapore Med J 1995;36:686-9
   PubMedGoogle Scholar
• Stone BD, Wheeler JG. Disseminated cryptococcal infection in a patient with hyperimmunoglobulinemia E syndrome. J Pediatr 1990;117:92-5
   PubMedGoogle Scholar
• Iseki M, Anzo M, Yamashita N, et al. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr 1994;83:780-2
   PubMed Web of Science ®Google Scholar
• Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 2013;190:3959-66
   PubMed Web of Science ®Google Scholar
• Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004;101:17258-63
   PubMed Web of Science ®Google Scholar
• Dixit A, Carroll SF, Qureshi ST. Cryptococcus gattii: an emerging cause of fungal disease in North America. Interdiscip Perspect Infect Dis 2009;2009:840452
   PubMedGoogle Scholar
• Galanis E, Macdougall L, Kidd S, et al. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010;16:251-7
   PubMed Web of Science ®Google Scholar
• Santos WR, Meyer W, Wanke B, et al. Primary endemic Cryptococcosis gattii by molecular type VGII in the state of Para, Brazil. Mem Inst Oswaldo Cruz 2008;103:813-18
   PubMedGoogle Scholar
• Lockhart SR, Iqbal N, Bolden CB, et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012;73:144-8
   PubMed Web of Science ®Google Scholar
• Byrnes EJ III, Bartlett KH, Perfect JR, et al. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect 2011;13:895-907
   PubMed Web of Science ®Google Scholar
• Severo CB, Xavier MO, Gazzoni AF, et al. Cryptococcosis in children. Paediatr Respir Rev 2009;10:166-71
   PubMedGoogle Scholar
• Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull 2004;72:99-118
   PubMed Web of Science ®Google Scholar
• Gumbo T, Kadzirange G, Mielke J, et al. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002;21:54-6
   PubMed Web of Science ®Google Scholar
• Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30:47-54
   PubMed Web of Science ®Google Scholar
• Denning DW, Armstrong RW, Lewis BH, et al. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-72
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48:856-62
   PubMed Web of Science ®Google Scholar
• Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008;86:647-51
   PubMedGoogle Scholar
• Popovich MJ, Arthur RH, Helmer E. CT of intracranial cryptococcosis. AJR Am J Roentgenol 1990;154:603-6
   PubMedGoogle Scholar
• Daunt N, Jayasinghe LS. Cerebral torulosis: clinical features and correlation with computed tomography. Clin Radiol 1985;36:485-90
   PubMedGoogle Scholar
• Charlier C, Dromer F, Leveque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 2008;3:e1950
   PubMed Web of Science ®Google Scholar
• Dromer F, Mathoulin-Pelissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007;4:e21
   PubMed Web of Science ®Google Scholar
• Patterson TF, Andriole VT. Current concepts in cryptococcosis. Eur J Clin Microbiol Infect Dis 1989;8:457-65
   PubMed Web of Science ®Google Scholar
• Cohen J. Comparison of the sensitivity of three methods for the rapid identification of Cryptococcus neoformans. J Clin Pathol 1984;37:332-4
   PubMedGoogle Scholar
• Thakur K, Singh G, Agarwal S, et al. Meningitis caused by Rhodotorula rubra in an human immunodeficiency virus infected patient. Indian J Med Microbiol 2007;25:166-8
   PubMedGoogle Scholar
• McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985;21:681-5
   PubMed Web of Science ®Google Scholar
• Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993;342:1119-20
   PubMedGoogle Scholar
• Govender NP, Patel J, van Wyk M, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother 2011;55:2606-11
   PubMed Web of Science ®Google Scholar
• van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21
   PubMed Web of Science ®Google Scholar
• Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7
   PubMed Web of Science ®Google Scholar
• Day JN, Chau TT, Lalloo DG. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368:2522-3
   PubMed Web of Science ®Google Scholar
• Huang KY, Huang YC, Hung IJ, et al. Cryptococcosis in nonhuman immunodeficiency virus-infected children. Pediatr Neurol 2010;42:267-70
   PubMedGoogle Scholar
• Davis JA, Horn DL, Marr KA, et al. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis 2009;11:432-7
   PubMedGoogle Scholar
• Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990;116:791-7
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Moran C, Benjamin DK Jr, et al. Pediatric antifungal agents. Curr Opin Infect Dis 2009;22:553-8
   PubMed Web of Science ®Google Scholar
• Chaudhary MW, Sardana K, Kumar P, et al. Disseminated infection with Cryptococcus neoformans var neoformans in an 8 years immunocompetent girl. Indian J Pediatr 2005;72:85
   Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29
   PubMedGoogle Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71
   PubMed Web of Science ®Google Scholar
• Al Arishi H, Frayha HH, Kalloghlian A, et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 1998;15:643-8
   PubMed Web of Science ®Google Scholar
• Manfredi R, Coronado OV, Mastroianni A, et al. Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Int J STD AIDS 1997;8:406-8
   PubMedGoogle Scholar
• Athanassiadou F, Tragiannidis A, Papageorgiou T, et al. Fungal brain abscesses in leukemia. Indian Pediatr 2006;43:991-4
   PubMedGoogle Scholar
• Bekersky I, Boswell GW, Hiles R, et al. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 1999;16:1694-701
   PubMed Web of Science ®Google Scholar
• Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-74
   PubMed Web of Science ®Google Scholar
• Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005;52:895-915, viii
   PubMedGoogle Scholar
• Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm 1988;7:424-38
   PubMedGoogle Scholar
• Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998;73:1205-25
   PubMed Web of Science ®Google Scholar
• Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-42
   PubMed Web of Science ®Google Scholar
• Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006;28:574-7
   PubMed Web of Science ®Google Scholar
• Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994;13:325-9
   PubMed Web of Science ®Google Scholar
• Viscoli C, Castagnola E, Fioredda F, et al. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991;35:365-7
   PubMed Web of Science ®Google Scholar
• Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999;43:1955-60
   PubMed Web of Science ®Google Scholar
• Powderly WG, Cloud GA, Dismukes WE, et al. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-92
   PubMed Web of Science ®Google Scholar
• Aberg JA, Price RW, Heeren DM, et al. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002;185:1179-82
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009;49:931-4
   PubMed Web of Science ®Google Scholar
• Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002;35:769-72
   PubMed Web of Science ®Google Scholar
• Parkes-Ratanshi R, Wakeham K, Levin J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis 2011;11:933-41
   PubMedGoogle Scholar
• Chang LW, Phipps WT, Kennedy GE, et al. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005;CD004773
   Google Scholar
• Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004;38:565-71
   PubMed Web of Science ®Google Scholar
• Negroni R, Helou SH, Lopez Daneri G, et al. Successful discontinuation of antifungal secondary prophylaxis in AIDS-related cryptococcosis. Rev Argent Microbiol 2004;36:113-17
   PubMedGoogle Scholar
• Sheng WH, Hung CC, Chen MY, et al. Successful discontinuation of fluconazole as secondary prophylaxis for cryptococcosis in AIDS patients responding to highly active antiretroviral therapy. Int J STD AIDS 2002;13:702-5
   PubMed Web of Science ®Google Scholar
• Nwokolo NC, Fisher M, Gazzard BG, et al. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001;15:1438-9
   PubMed Web of Science ®Google Scholar
• Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 2005;80:1033-9
   PubMed Web of Science ®Google Scholar
• Zar HJ. Global paediatric pulmonology: out of Africa. Paediatr Respir Rev 2006;7(Suppl 1):S226-8
   Google Scholar
• Kroidl A, Huck K, Weinspach S, et al. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child. Scand J Infect Dis 2006;38:716-18
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006;25:53-8
   PubMedGoogle Scholar
• Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46:1694-701
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005;51:e289-97
   PubMedGoogle Scholar
• Natukunda E, Musiime V, Ssali F, et al. A case of Cryptococcal Lymphadenitis in an HIV-infected child. AIDS Res Hum Retroviruses 2011;27:373-6
   PubMedGoogle Scholar
• Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007;7:395-401
   PubMed Web of Science ®Google Scholar
• Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010;202:962-70
   PubMed Web of Science ®Google Scholar
• Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005;19:1043-9
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010;50:1532-8
   PubMed Web of Science ®Google Scholar
• Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406
   PubMed Web of Science ®Google Scholar
• Boulware DR, Meya D, Muzoora C, et al. ART initiation within the first 2 weeks of cryptococcal meningitis is associated with higher mortality: a multisite randomized trial. 20th Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2013; Atlanta, Georgia
   Google Scholar
• McMullan BJ, Halliday C, Sorrell TC, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One 2012;7:e49541
   PubMed Web of Science ®Google Scholar
• Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011;53:321-5
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011;53:1019-23
   PubMed Web of Science ®Google Scholar
• Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012;59:e85-91
   PubMed Web of Science ®Google Scholar
• Sweeney DA, Caserta MT, Korones DN, et al. A ten-year-old boy with a pulmonary nodule secondary to Cryptococcus neoformans: case report and review of the literature. Pediatr Infect Dis J 2003;22:1089-93
   PubMedGoogle Scholar
• Veron V, Simon S, Blanchet D, et al. Real-time polymerase chain reaction detection of Cryptococcus neoformans and Cryptococcus gattii in human samples. Diagn Microbiol Infect Dis 2009;65:69-72
   PubMedGoogle Scholar
• Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012;26:1105-13
   PubMed Web of Science ®Google Scholar
• Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-91
   PubMed Web of Science ®Google Scholar
• Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother 2001;45:686-9
   PubMed Web of Science ®Google Scholar
• Herrmann JL, Dubois N, Fourgeaud M, et al. Synergic inhibitory activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophages. J Antimicrob Chemother 1994;34:1051-8
   PubMed Web of Science ®Google Scholar
• Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001;107:E66
   PubMed Web of Science ®Google Scholar
• Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013;13:629-37
   PubMed Web of Science ®Google Scholar
• Jackson AT, Nussbaum JC, Phulusa J, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS 2012;26:1363-70
   PubMed Web of Science ®Google Scholar
• Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009;49:702-9
   PubMed Web of Science ®Google Scholar
• Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5
   PubMed Web of Science ®Google Scholar
• Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998;26:1362-6
   PubMed Web of Science ®Google Scholar